These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29415334)

  • 1. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
    Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
    Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
    Pilgrim H; Lloyd-Jones M; Rees A
    Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
    Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
    Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
    BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
    Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
    BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis.
    Yang H; Llewellyn A; Walker R; Harden M; Saramago P; Griffin S; Simmonds M
    BMC Med; 2019 Feb; 17(1):37. PubMed ID: 30760268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews.
    Ryczek E; White J; Carolan-Rees G
    Transfus Med; 2020 Aug; 30(4):287-294. PubMed ID: 32447792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
    Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
    Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
    Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
    Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive Fetal RhD Blood Group Genotyping: A Systematic Review of Economic Evaluations.
    Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Higgins C; Shehata N; Okun N; de Vrijer B; Pechlivanoglou P; Ng V; Sikich N
    J Obstet Gynaecol Can; 2021 Dec; 43(12):1416-1425.e5. PubMed ID: 34390866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.